When a preclinical study is being planned, there is a decision that is rarely given the weight it deserves: where we do it. Because “where” is not simply a question of capacity.

This is a matter of regulation. Oversight from agencies such as the EMA and the FDA has tightened (Grand View Research, 2026), and this turns the initial design of a study into the element that decides what happens months, or years, later: whether the data arrive at audit ready to be reviewed, or whether they need to be repeated. Bridging studies, additional documentation, time lost exactly when the regulatory timeline matters most.

This is a matter of know how. Versa Biomedical’s Certified Rigor Framework is not a response to an audit, it is the criterion that guides the design from day one: triple certification, ad hoc expert teams, and an integral study design built so that the data arrive at the clinical phase with stronger guarantees, not because they need to be adapted later.

This is a matter of continuity between the preclinical and clinical phases. We work from Barcelona, one of the most active biomedical hubs in Europe: a network of hospitals, research centres, and companies where, often, the same contacts from the preclinical phase reappear in the clinical phase.

This is a matter of accessibility. Site visits, validations with the surgeons, and direct oversight of the study are resolved with a straightforward trip, not weeks of planning.

At Versa Biomedical, we have the regulation, the know how, the continuity between the preclinical and clinical phases and the accesibility.

So we return to the original question. Where a study is conducted is not a matter of logistics. It is the strategic decision made before the science even begins, and the one that opens the path for these innovations to reach those who need them most.

#OpenModelsOpenFutures